NCT06258408View on ClinicalTrials.gov

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

July 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

BB102 tablet

BB102 tablets will be administered orally once daily(QD).

Trial Locations (2)

Unknown

RECRUITING

Nanfang Hospital, Guangzhou

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

BrodenBio Co., Ltd.

INDUSTRY